scholarly journals Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

Diabetes ◽  
2013 ◽  
Vol 62 (11) ◽  
pp. 3766-3774 ◽  
Author(s):  
K. C. Herold ◽  
S. E. Gitelman ◽  
M. R. Ehlers ◽  
P. A. Gottlieb ◽  
C. J. Greenbaum ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Type 1 Diabetes ◽  
Controlled Trial ◽  
C Peptide ◽  
Onset Type ◽  
Randomized Controlled ◽  
New Onset

Effect of a single autologous cord blood infusion on beta-cell and immune function in children with new onset type 1 diabetes: a non-randomized, controlled trial

2013 ◽  
Vol 15 (2) ◽  
pp. 100-109 ◽  
Author(s):  
Eleni Z Giannopoulou ◽  
Ramona Puff ◽  
Andreas Beyerlein ◽  
Irene von Luettichau ◽  
Heike Boerschmann ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Type 1 Diabetes ◽  
Beta Cell ◽  
Cord Blood ◽  
Immune Function ◽  
Controlled Trial ◽  
Onset Type ◽  
Randomized Controlled ◽  
New Onset

scholarly journals Effect of 6 Months of Flash Glucose Monitoring in Youth With Type 1 Diabetes and High-Risk Glycemic Control: A Randomized Controlled Trial

Diabetes Care ◽  
2020 ◽  
Vol 43 (10) ◽  
pp. 2388-2395 ◽  
Author(s):  
Sara E. Boucher ◽  
Andrew R. Gray ◽  
Esko J. Wiltshire ◽  
Martin I. de Bock ◽  
Barbara C. Galland ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Type 1 Diabetes ◽  
High Risk ◽  
Glycemic Control ◽  
Controlled Trial ◽  
Glucose Monitoring ◽  
Flash Glucose Monitoring ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document